PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Phenotypic Detection of Carbapenemase and AmpC‐β‐Lactamase Production among Extended Spectrum β‐Lactamase (ESBL)‐Producing Escherichia coli and Klebsiella spp., Isolated from Clinical Specimens
Garba, Z.; Kaboré, B.; Bonkoungou, I.J.O.; Natama, M.H.; Rouamba, T.; Haukka, K.; Kirveskari, J.P.; Tinto, H.; Sangaré, L.; Barro, N.; Kantele, A. Phenotypic Detection of Carbapenemase and AmpC-β-Lactamase Production among Extended Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella spp. Isolated from Clinical Specimens. Antibiotics2024, 13, 31.
Garba, Z.; Kaboré, B.; Bonkoungou, I.J.O.; Natama, M.H.; Rouamba, T.; Haukka, K.; Kirveskari, J.P.; Tinto, H.; Sangaré, L.; Barro, N.; Kantele, A. Phenotypic Detection of Carbapenemase and AmpC-β-Lactamase Production among Extended Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella spp. Isolated from Clinical Specimens. Antibiotics 2024, 13, 31.
Garba, Z.; Kaboré, B.; Bonkoungou, I.J.O.; Natama, M.H.; Rouamba, T.; Haukka, K.; Kirveskari, J.P.; Tinto, H.; Sangaré, L.; Barro, N.; Kantele, A. Phenotypic Detection of Carbapenemase and AmpC-β-Lactamase Production among Extended Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella spp. Isolated from Clinical Specimens. Antibiotics2024, 13, 31.
Garba, Z.; Kaboré, B.; Bonkoungou, I.J.O.; Natama, M.H.; Rouamba, T.; Haukka, K.; Kirveskari, J.P.; Tinto, H.; Sangaré, L.; Barro, N.; Kantele, A. Phenotypic Detection of Carbapenemase and AmpC-β-Lactamase Production among Extended Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella spp. Isolated from Clinical Specimens. Antibiotics 2024, 13, 31.
Abstract
Background
In many African countries, clinical samples are not routinely tested for carbapenem-resistant bacteria, the resistance data remaining limited.
Material and methods
In March 2020 –June 2022, we collected extended spectrum β-lactamase (ESBL) -producing Enterobacterales (ESBL-PE) isolates from five hospitals in Burkina Faso. The species were identified using API20E and ESBL production confirmed by double-disc synergy test. Production of carbapenemases and AmpC-β-lactamases and phenotypic co-resistance were determined.
Results
Among the 473 ESBL-PE, 356 were ESBL- E. coli (ESBL-Ec) and 117 Klebsiella spp. (ESBL-K). Of the isolates, 5.3% were carbapenemase and 5.3% AmpC-β-lactamase positive Three types of carbapenemases were identified: 19 NDM, 3 OXA-48 like and 1 VIM. Two isolates produced both NDM and OXA48-like carbapenemases. Carbapenemase rates were highest among isolates in tertiary hospitals. Co-resistance rates were up to 85% for aminoglycosides, 90% for sulfonamides, 95% for fluoroquinolones and 25% for chloramphenicol, Fosfomycin resistance was 6% for ESBL-Ec and 49% for ESBL-K (49%).
Conclusion
Many ESBL-Ec and ESBL-K co-produced carbapenemases and/or AmpC-β-lactamases, at all healthcare levels and in various samples, with high co-resistance rates to non-betalactams. Carbapenem resistance is no longer rare, calling for testing in routine diagnostics, vigorous resistance surveillance system, and infection control within healthcare.
Keywords
ESBL; carbapenemase; AmpC‐β‐lactamase; E. coli; Klebsiella spp; hospitals
Subject
Public Health and Healthcare, Other
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.